Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.


'Encouraging' Ebola drug results in Guinea

05 February 2015, 21:26

Paris - For the first time since the west African Ebola outbreak began over a year ago, a clinical trial with a candidate treatment has yielded "encouraging" results, researchers announced Thursday.

The trial with 80 patients in Guinea resulted in fewer deaths and faster recovery rates, the French government and medical research agency Inserm said of tests with the Japanese-manufactured anti-viral drug favipiravir.

Also read: African Union meets on force to fight Boko Haram

No scientific trial data has been made public, but the outcome was said to offer "hope" for tackling the haemorrhagic fever virus that has infected 22,495 people and killed 8,981 in the worst Ebola outbreak in history, according to the latest World Health Organization tally.

"Encouraging results of the trial will be submitted shortly to a scientific journal for publication," Inserm said in a statement to AFP.

The French presidency said in a separate statement the trial showed "a reduction in the number of deaths among adults and teenagers, with slower virus multiplication. Recovery is accelerated".

'Important step forward'

The head of France's Ebola Task Force, Jean-Francois Delfraissy, and Inserm head Yves Levy briefed President Francois Hollande and government officials on Wednesday, it added, and described the results as "an important step forward".

Inserm is in charge of the trial at a treatment centre in Gueckedou in the east of Guinea -- one of the three countries, with Liberia and Sierra Leone, hardest hit by the outbreak.

The trial, which started on December 17, was conducted with Guinean researchers and authorities, non-government organisations, the French Red Cross and aid group Doctors Without Borders (MSF).

It is the largest clinical trial yet with a candidate Ebola treatment, the French statement said.

Favipiravir, also known as Avigan, is developed by Toyama Chemical, a subsidiary of Fujifilm Holdings.

Inserm said the scientific results will be made public once they have been officially reviewed and validated by the scientific community, which could happen by month's end.

Emergency treatment

The drug has already been administered as an emergency treatment to patients evacuated from West Africa to Europe, though this was not part of an official trial.

It has commercial authorisation in Japan as a flu medicine, and large doses can be made quickly available an advantage over other experimental treatments, like ZMapp, of which stocks are limited.

The Japanese company said last year it had sufficient reserves for more than 20,000 people.

The Elysee said the results gave rise to "hope", but cautioned they have to be confirmed with a larger group of trial patients.

"These early results open new avenues for access to treatment in the fight against this disease," it said.

MSF said in December that "if favipiravir is shown to be safe and effective, it will be made accessible to Ebola patients in other Ebola treatment centres through advancing the trial to the next phase.

"This means that after approval from national authorities and independent ethics committees more Ebola positive patients in west Africa will be placed on the treatment."

There is as yet no licenced vaccine or treatment for Ebola.

The WHO gave the green light last August for experimental treatment to be used in the current crisis, and several candidate drugs are being fast-tracked through the normally years-long trial process.

Ebola, one of the deadliest viruses known to man, is spread through direct contact with the bodily fluids of an infected person showing symptoms such as fever or vomiting.

People caring for the sick or handling corpses are at highest risk, and the disease is best contained by limiting exposure through patient isolation and safe burials.

A sharp drop in new cases in recent weeks gave rise to optimism that the worst was over, but the WHO on Wednesday reported the first rise for 2015 in the weekly number of cases in all three countries.

A trial with another candidate treatment, brincidofovir, was halted in Liberia Tuesday.

The trial's funder, the Wellcome Trust research charity, cited dropping patient numbers and said there was "no realistic prospect of the trial enrolling sufficient patients to be able to reach a conclusion about the efficacy of the drug."

The first large-scale trials with two Ebola vaccines started in Liberia on Monday.



Read News24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Read more from our Users

Nigeria @ 56: Words to my green f...

A leader’s job is not to dictate, but rather to be respected, admired and be a trustee, of the land we love, with so much potential, a land which should be freer than free. Its still a long way to fufilling our destiny! Read more...

Submitted by
Isaac Asabor263
Recession: An opportunity for Nig...

The recession should be seen as an opportunity for the country’s promotion as long as we all collectively conduct ourselves in a patriotic manner, writes Isaac Asabor.  Read more...

Submitted by
Black and White

We want to imitate the whites in everything because we are ignorant of our inherent originality and content. We spend all our Naira to acquire his inventions because we so oblivious of our natural endowments that we allow him have it for free. Read more...

Submitted by
Nate Nat
Adamawa State University Mubi: A ...

ADSU integrity forum has accused the Sunday Joshua Wugira, a lawyer, of adopting unorthodox tactics by abusing his privilege by attacking the integrity of ADSU Vice Chancellor Dr. Moses Zira Zaruwa, writes a News24 reader. Read more...

Submitted by
Abdulsalam Jubril
My Country Nigeria (Part One)

Poetry by Abdulsalam Jubril.

Submitted by
Abdulsalam Jubril
Recession, dearth in leadership a...

Every leader has the opportunity to become great and making himself immortal in the lives and hearts of people for generations to come. Will Mr. President seize this opportunity?, questions Abdulsalam Jubril. Read more...